{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:22:49Z","timestamp":1787844169667,"version":"build-2784847793"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20201175"],"award-info":[{"award-number":["BK20201175"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171441"],"award-info":[{"award-number":["82171441"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.yebeh.2023.109353","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T07:47:55Z","timestamp":1690012075000},"page":"109353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: A prospective study evaluating efficacy, tolerability, and behavior"],"prefix":"10.1016","volume":"146","author":[{"given":"Rui","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Qin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10282","key":"10.1016\/j.yebeh.2023.109353_b0005","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109353_b0010","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109353_b0015","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","volume":"4","author":"Nevitt","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2023.109353_b0020","unstructured":"Food and Drug Administration (FDA). FYCOMPA\u00ae prescribing information; December 2021."},{"issue":"2","key":"10.1016\/j.yebeh.2023.109353_b0025","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/epi4.12398","article-title":"Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open-label Study 342 (FREEDOM Study)","volume":"5","author":"Yamamoto","year":"2020","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2023.109353_b0030","article-title":"Plasma lacosamide monitoring in children with epilepsy: Focus on reference therapeutic range and influencing factors","volume":"10","author":"Li","year":"2022","journal-title":"Front Pediatr"},{"issue":"12","key":"10.1016\/j.yebeh.2023.109353_b0035","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nrd2764","article-title":"Lacosamide","volume":"7","author":"Perucca","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109353_b0040","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10072-016-2512-2","article-title":"Dose effects of lacosamide as add-on therapy for partial-onset seizure in adult","volume":"37","author":"Chen","year":"2016","journal-title":"Neurol Sci"},{"issue":"12","key":"10.1016\/j.yebeh.2023.109353_b0045","first-page":"e1212","article-title":"Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures","volume":"93","author":"Farkas","year":"2019","journal-title":"Neurol"},{"key":"10.1016\/j.yebeh.2023.109353_b0050","unstructured":"National Library of Medicine (U.S). Efficacy and safety of lacosamide as adjunctive therapy in subjects \u22651 month to <4 years with partial-\u00adonset seizures. Identifier: NCT02477839."},{"key":"10.1016\/j.yebeh.2023.109353_b0055","doi-asserted-by":"crossref","DOI":"10.1111\/epi.17187","article-title":"Safety and tolerability of short-term infusions of intravenous lacosamide in pediatric patients with epilepsy: an open-label, phase 2\/3 trial","author":"Farkas","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2023.109353_b0060","article-title":"Safety, efficacy, and tolerability of lacosamide for the treatment of epilepsy in pediatric patients in Uygur","volume":"117","author":"Zhao","year":"2021","journal-title":"China Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.yebeh.2023.109353_b0065","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/epi.13417","article-title":"Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety","volume":"57","author":"Lagae","year":"2016","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109353_b0070","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ane.12529","article-title":"Perampanel for focal epilepsy: insights from early clinical experience","volume":"133","author":"Trinka","year":"2016","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"10.1016\/j.yebeh.2023.109353_b0075","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2023.109353_b0080","article-title":"Perampanel tolerability in children and adolescents with focal epilepsy: effects on behavior and executive functions","volume":"103","author":"Operto","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109353_b0085","unstructured":"Eisai Co., Ltd. (per EMA). Perampanel label; 2021."},{"issue":"3","key":"10.1016\/j.yebeh.2023.109353_b0090","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1037\/pas0001083","article-title":"Linking the child behavior checklist to the strengths and difficulties questionnaire","volume":"34","author":"Mansolf","year":"2022","journal-title":"Psychol Assess"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109353_b0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1469-7610.2007.01867.x","article-title":"Multicultural assessment of child and adolescent psychopathology with ASEBA and SDQ instruments: research findings, applications, and future directions","volume":"49","author":"Achenbach","year":"2008","journal-title":"J Child Psychol Psychiatry"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109353_b0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/epi4.12555","article-title":"A retrospective, real-world experience of perampanel monotherapy in patient with first new onset focal seizure: a Thailand experience","volume":"7","author":"Chinvarun","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2023.109353_b0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.seizure.2017.10.015","article-title":"A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy","volume":"54","author":"Gil-Nagel","year":"2018","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109353_b0110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/ane.12920","article-title":"Lacosamide monotherapy in clinical practice: a retrospective chart review","volume":"138","author":"Villanueva","year":"2018","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109353_b0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejpn.2011.08.007","article-title":"Preliminary efficacy and safety of lacosamide in children with refractory epilepsy","volume":"16","author":"Heyman","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2023.109353_b0120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.yebeh.2017.11.024","article-title":"The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting","volume":"79","author":"Sanmart\u00ed-Vilaplana","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109353_b0125","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/epi.16548","article-title":"Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: experience from a national multicenter registry","volume":"61","author":"Toledano Delgado","year":"2020","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2023.109353_b0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/epi4.12575","article-title":"PROVE: Retrospective, non-interventional, Phase IV study of perampanel in real-world clinical care of patients with epilepsy","volume":"7","author":"Wechsler","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2023.109353_b0135","first-page":"1","article-title":"Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies","volume":"9","author":"Kwan","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109353_b0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(16)30292-7","article-title":"Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"16","author":"Baulac","year":"2017","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109353_b0145","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109353_b0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"issue":"18","key":"10.1016\/j.yebeh.2023.109353_b0155","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109353_b0160","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ane.12883","article-title":"Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study","volume":"137","author":"Nishida","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2023.109353_b0165","unstructured":"Eisai Co., Ltd. (per PMDA). Perampanel label; 2020."},{"issue":"126","key":"10.1016\/j.yebeh.2023.109353_b0170","first-page":"201","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study","volume":"2016","author":"Villanueva","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2023.109353_b0175","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.yebeh.2018.06.033","article-title":"Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: the first real-world evaluation in Asian pediatric neurology clinics","volume":"85","author":"Lin","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109353_b0180","unstructured":"Eisai Ltd. Fycompa Summary of Product Characteristics: Electronic Medicines Compendium; 2014. https:\/\/www.medicines.org.uk\/emc\/medicine\/26951"},{"key":"10.1016\/j.yebeh.2023.109353_b0185","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yebeh.2016.04.049","article-title":"The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy","volume":"61","author":"Lancman","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109353_b0190","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.yebeh.2017.05.001","article-title":"Effects of adjunctive lacosamide on mood and quality of life in patients with epilepsy","volume":"73","author":"Nakhutina","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109353_b0195","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.yebeh.2017.10.032","article-title":"Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: a prospective multicenter study","volume":"79","author":"Rocamora","year":"2018","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502300272X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502300272X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:49:55Z","timestamp":1761504595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502300272X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":39,"alternative-id":["S152550502300272X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109353","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: A prospective study evaluating efficacy, tolerability, and behavior","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109353"}}